The pharmacokinetic profile of tiagabine

Reviews in Contemporary Pharmacotherapy

Volumn 12, Issue 5, 2002, Pages 225-233

  Wang, Xiaolan ^a   Patsalos, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DIGOXIN; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; THEOPHYLLINE DERIVATIVE; TIAGABINE; TRIAZOLAM; VALPROIC ACID; WARFARIN;

ADOLESCENT; ADULT; AGED; CHILD; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; HUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; REVIEW;

EID: 0036343656     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Adjunctive tiagabine compared with phenytoin and carbamazepine in the multicenter, double-blind trial of complex partial seizures
2. 14C-tiagabine in humans
3. 14C] tiagabine by human hepatic microsomes
4. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-lyl]nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake barrier
5. Tiagabine pharmacology in profile
6. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine
7. Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine
8. Stereoselective central nervous effects of the R- and S-isomers of the GABA uptake blocker N-(4,4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat
9. Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed
10. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus
11. 3H] tiagabine binding to GABA uptake sites in human brain
12. High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection
13. Pharmacokinetics of tiagabine, a γ-aminobutyric acid uptake inhibitor, in healthy subjects after single and multiple doses
14. A single-dose study to define tiagabine pharmacokinetics in paediatric patients with complex partial seizures
15. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin
16. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate
17. Population pharmacokinetics of tiagabine in epileptic patients on monotherapy
18. Absolute bioavailability of tiagabine
19. Tiagabine: Absence of kinetic or dynamic interactions with ethanol
20. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function
21. Synergism with GABAergic drugs in refractory epilepsy
22. Deliberate overdose with the novel anticonvulsant tiagabine
23. Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex
24. Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsants? Experience with four anticonvulsant drugs
25. Effect of food on the bioavailability of tiagabine HCl
26. An evaluation of the interaction between tiagabine and oral contraceptives on female volunteers
27. Tiagabine: Evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol
28. Poisoning by anticonvulsants
29. Successful tiagabine monotherapy during pregnancy and lactation: Clinical and serum data
30. New antiepileptic drugs
31. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
32. Therapeutic drug monitoring: The established and the new antiepileptic drugs
33. The pharmacology and pharmacokinetics of vigabatrin
34. Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy
35. Concentration-dependent serum protein displacement of tiagabine by valproic acid
36. Blood and cerebrospinal fluid kinetics of tiagabine in rats
37. The kinetics of tiagabine in blood and extracellular fluid, frontal cortex and hippocampus: A microdialysis study
38. Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial
39. Absence of interaction between tiagabine, a new antiepileptic drug, and the benzodiazepine triazolam
40. Dose concentration relationship in a multicentre tiagabine (Gabitril™ trial)
41. Tiagabine therapy for complex partial seizures. A dose-frequency study
42. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy
43. Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition
44. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy
45. Tiagabine, a novel antiepileptic agent: Lack of pharmacokinetic interaction with digoxin
46. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs
47. 3H]tiagabine (NNC 05-328) to the GABA uptake carrier
48. Lack of pharmacokinetic interaction between tiagabine and erythromycin
49. Clinical pharmacokinetics of new antiepileptic drugs